A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years
NCT02269488
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy Japanese Children Age 2 Years Through 6 Years
Interventions
DRUG:
MEDI3250
Sponsor
AstraZeneca